Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23234973 | 0.87 | MAPK1 (0.76) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL531233 | 0.86 | MAPK1 (0.81) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL27242942 | 0.85 | GAA (0.55) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL23634709 | 0.84 | MAPK1 (0.71) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL10322395 | 0.84 | GAA (0.81) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL18631940 | 0.83 | RXFP1 (0.52) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL3782311 | 0.83 | GAA (0.67) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL17272569 | 0.83 | MAPK1 (0.66) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL18843746 | 0.83 | MAPK1 (0.66) | GAARXFP1NPSR1MAPK1AURKB | |
| SCHEMBL18998183 | 0.82 | AURKB (0.75) | GAARXFP1NPSR1MAPK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174279-B | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | disclosed |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | disclosed |
| EP-4010317-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3683220-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTINGTON'S DISEASE | ASTRAZENECA AB (SE) | 2022-04-13 | — | — | EP | disclosed |
| CN-114174279-A | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20210147416-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| WO-2017194632-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017076898-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017076895-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017076898-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017076895-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017046216-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| WO-2017046216-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147416-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | GAA 1057/4885RXFP1 2596/4885NPSR1 4144/4885 |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | GAA 1089/4885RXFP1 2611/4885NPSR1 4196/4885 |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | GAA 1089/4885RXFP1 2611/4885NPSR1 4196/4885 |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | GAA 1089/4885RXFP1 2611/4885NPSR1 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.